Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | ADK | P55263 | 6/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | ABL2 | P42684 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28057750 | 0.87 | FGFR1 (0.49) | SRCEGFRADKMTORRAB9A | |
| SCHEMBL29503400 | 0.86 | SRC (0.64) | SRCEGFRADKMTORRAB9A | |
| SCHEMBL1444035 | 0.86 | SRC (0.64) | SRCEGFRADKMTORRAB9A | |
| SCHEMBL16236406 | 0.85 | RET (0.52) | SRCEGFRADKMTORRAB9A | |
| SCHEMBL399455 | 0.85 | ADK (0.47) | SRCEGFRADKMTORRAB9A | |
| SCHEMBL399456 | 0.85 | ADK (0.47) | SRCEGFRADKMTORRAB9A | |
| SCHEMBL10225976 | 0.85 | ADK (0.47) | SRCEGFRADKMTORRAB9A | |
| SCHEMBL27217643 | 0.84 | HASPIN (0.53) | SRCEGFRADKMTORRAB9A | |
| SCHEMBL28662316 | 0.82 | MTOR (0.47) | SRCADKMTORRAB9AHASPIN | |
| SCHEMBL28662315 | 0.82 | MTOR (0.47) | SRCADKMTORRAB9AHASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | SRC 222/4885EGFR 1510/4885ADK 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.